Online citations, reference lists, and bibliographies.
← Back to Search

Population Based Epidemiology And Prognosis Of Mesothelioma In Leeds, UK

A. Chapman, S. Mulrennan, B. Ladd, M. Muers
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: Malignant mesothelioma is a fatal neoplasm, which is rapidly increasing in incidence throughout Western Europe. To date there have been no studies reporting on the natural history and interventional practices on a comprehensive unselected population, as opposed to reports from referral institutions or compensation claimants. We present a population based study capturing data on all patients with mesothelioma presenting within a defined geographical area over a 4 year period in the UK. Method: Data of all cases occurring in Leeds with a population of 750 000 were collected retrospectively from 2002 to 2003 and prospectively from 2004 to 2005. All patients’ hospital records and the Trust histology database were reviewed, as well as coroner’s reports on all patients with a post mortem diagnosis of mesothelioma. Results: Over the 4 year study period, there were a total of 146 cases in Leeds; 77% were male. Median age was 74 years (range 36–93). Median survival from diagnosis was 8.9 months. 92% and 8% had histological or cytological confirmation, respectively. 85% had documented evidence of definite or probable exposure to asbestos. 110/146 (75%) had symptomatic pleural effusions at presentation. Twice the number of patients (42 vs 17) were managed with surgical rather than bedside pleurodesis and these had a lower recurrence rate (14% vs 47%; p = 0.02). 122 patients had video assisted thoracoscopic surgery/cutting CT biopsies or chest drains. 73/122 (60%) had prophylactic radiotherapy to these sites. There were seven cases (5%) of tract invasion by tumour and six of these had received prophylactic radiotherapy. Median time to seeding was 174 days. 92/146 (63%) had a performance status of 2 or better at diagnosis but only 54/146 were considered fit for chemotherapy. Of these, 28 (52%) declined chemotherapy; the overall uptake of chemotherapy or entry into a trial was 18%. No patient had radical surgery. Conclusion: This comprehensive population based audit has shown that the median age at presentation of malignant mesothelioma is increasing and baseline performance status and survival is worse than in selected series. 37% of patients were considered suitable for palliative chemotherapy but less than 20% accepted this offer. Thorascopic pleurodesis appears to be associated with fewer recurrences. The role of prophylactic radiotherapy to chest drain and biopsy sites needs reappraisal.
This paper references
10.1136/THORAX.58.SUPPL_2.II29
BTS guidelines for the management of malignant pleural effusions.
G. Antunes (2003)
Palliative care in mesothelioma : What are the needs of patients and their families . Thesis in preparation BTS guidelines for the management of malignant pleural effusions
H Clayson (2005)
Palliative care in mesothelioma: What are the needs of patients and their families
H Clayson
Stenius-Aarniala B. Fire-eater’s lung
PE Brander (1992)
10.1136/oem.54.6.403
Routes of asbestos exposure and the development of mesothelioma in an English region.
D. Howel (1997)
10.1136/adc.67.11.1376
Bronchoscopy in lipoid pneumonia.
M. Kameswaran (1992)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1002/PATH.1711430303
Diagnosis of pleural malignant mesothelioma in life—a practical approach
D. Whitaker (1984)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1002/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W
Malignant mesothelioma of the pleura: Review of 123 patients
J. Brenner (1982)
Pleural mesotheliomas : clinical experience with 37 patients
ER Ratzer (1967)
10.1183/09031936.96.09071463
Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France.
A. Gondouin (1996)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.7326/0003-4819-134-10-200105150-00021
Textbook of Lung Cancer
M. C. Perry (2001)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1378/CHEST.124.6.2229
Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists.
Y. Lee (2003)
10.1097/00004728-200005000-00017
Fire eater's pneumonia: radiographic and CT findings.
T. Franquet (2000)
10.1093/ANNONC/MDI094
Chemotherapy options and new advances in malignant pleural mesothelioma.
J. Steele (2005)
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
M. Law (1984)
10.1002/JAT.2550100213
Toxicology update isoparaffinic hydrocarbons: A summary of physical properties, toxicity studies and human exposure data
L. S. Mullin (1990)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1093/AJCP/82.1.15
Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study.
V. Adams (1984)
10.1136/thorax.56.4.250
Statement on malignant mesothelioma in the United Kingdom
T. British (2001)
Malignant mesothelioma . In : Hanson , ed . Textbook of lung cancer
B Scott (2000)
10.1136/oem.49.10.732
Survival of asbestos insulation workers with mesothelioma.
J. Ribak (1992)
10.1093/OXFORDJOURNALS.QJMED.A067473
The clinical aspects of mesothelioma.
P. Elmes (1976)
Fire-eater's lung.
P. Brander (1992)
10.1136/thx.26.1.6
Diffuse malignant pleural mesothelioma and asbestos exposure
F. Whitwell (1971)
Aspects evoltifs des mesotheliomes pleuraux diffuse
AY DeLajartre (1979)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
Subcutaneous tumor growth complicating the positioning of Denver shunt and intrapleural port-à-cath in mesothelioma patients.
B. van Ooijen (1992)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1136/oem.56.1.51
Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.
D. Howel (1999)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
Subcutaneous tumour growth complicating the positioning of the Denver shunt and intrapleural portacath in mesothelioma patients
B VanOoijen (1992)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.3109/9781439802014
Textbook of Lung Cancer
H. Hansen (1999)
La Levi F , Negri E . The European mesothelioma epidemic
J Peto (1999)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1002/(SICI)1097-0142(19990101)85:1<250::AID-CNCR41>3.0.CO;2-3
The use of epithelial membrane antigen and silver‐stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses
K. Metze (1999)
10.1378/CHEST.127.3.909
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
C. Dresler (2005)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)



This paper is referenced by
10.1378/chest.09-1951
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
S. Savic (2010)
10.1186/s12885-018-4113-3
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
D. de Fonseka (2018)
10.1007/978-3-030-18944-0
Integrated Palliative Care of Respiratory Disease
S. Bourke (2019)
10.1016/j.lungcan.2008.09.008
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
10.1111/cas.12769
Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue
T. Hida (2015)
10.3390/medicina55080419
Mesothelioma Mortality Rates in Greece for the Period 2005–2015 Is Increased Compared to Previous Decades
Evdoxia Gogou (2019)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.1097/ACI.0b013e32832921f3
Lessons from ecological and spatial studies in relation to occupational lung disease
A. Hansell (2009)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.
M. Corradi (2013)
10.17795/RRO-3835
Pain Management in Mesothelioma
N. Macleod (2015)
10.1007/978-1-4471-2230-2_7
Pleural Effusions and Mesothelioma
C. Stenton (2013)
10.1002/dc.23501
Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations
K. Nabeshima (2016)
10.1634/theoncologist.2018-0501
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
S. V. Soldera (2018)
10.1016/j.clon.2013.08.009
Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival.
S. Murphy (2013)
10.1038/bjc.2015.77
The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial
D. Arnold (2015)
10.1016/j.lungcan.2009.06.014
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
C. Lee (2009)
10.1038/bjc.2015.62
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
C. Hooper (2015)
10.1016/j.radonc.2011.08.038
Prophylactic irradiation of intervention sites in malignant pleural mesothelioma.
Marie-Anne Froment (2011)
10.1186/1471-2407-9-28
Certified causes of death in patients with mesothelioma in South East England
C. Okello (2008)
10.1093/ejcts/ezr192
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
A. Nakas (2012)
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
Using Radiotherapy to Treat Pain in Mesothelioma
Nicholas Macleod (2015)
10.2147/OTT.S134126
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma
K. Aigner (2017)
10.1038/bjc.2012.245
Prognosis and prognostic factors of patients with mesothelioma: a population-based study
S. van der Bij (2012)
10.1111/pin.12973
Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
Yoshiaki Kinoshita (2020)
Soluble mesothelin-related protein in malignant pleural mesothelioma.
H. Azim (2008)
10.1684/BDC.2013.1857
Mésothéliomes malins pleuraux : le point en 2013
Karine Campbell (2013)
10.1183/09031936.00000811
Predicting survival in malignant mesothelioma
A. Musk (2011)
10.1007/978-1-4471-2230-2
Integrated palliative care of respiratory disease
S. Bourke (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar